Gao Yang, Fan Wan-Hung, Song Zhengbo, Lou Haizhou, Kang Xixong
Key Laboratory for Biomechanics and Mechanobiology of Ministry of Education, School of Biological Science and Medical Engineering, Beihang University, Beijing, China.
Beijing Advanced Innovation Center for Biomedical Engineering, Beijing Polytechnic University, Beijing, China.
PeerJ. 2021 Mar 2;9:e10777. doi: 10.7717/peerj.10777. eCollection 2021.
Status of epithelial-mesenchymal transition (EMT) varies from tumors to tumors. Epithelial cell adhesion molecule (EpCAM) and cell surface vimentin (CSV) are the most common used targets for isolating epithelial and mesenchymal CTCs, respectively. This study aimed to identify a suitable CTC capturing antibody for CTC enrichment in each solid tumor by comparing CTC detection rates with EpCAM and CSV antibodies in different solid tumors.
Treatment-naive patients with confirmed cancer diagnosis and healthy people who have performed CTC detection between April 2017 and May 2018 were included in this study. CTC detection was performed with CytoSorter CTC system using either EpCAM or CSV antibody. In total, 853 CTC results from 690 cancer patients and 72 healthy people were collected for analysis. The performance of CTC capturing antibody was determined by the CTC detection rate.
EpCAM has the highest CTC detection rate of 84.09% in CRC, followed by BCa (78.32%). CTC detection rates with EpCAM antibody are less than 40% in HCC (25%), PDAC (32.5%) and OC (33.33%). CSV has the highest CTC detection rate of 90% in sarcoma, followed by BC (85.71%), UC (84.62%), OC (83.33%) and BCa (81.82%). CTC detection rates with CSV antibody are over 60% in all 14 solid tumors. Except for CRC, CSV has better performances than EpCAM in most solid tumors regarding the CTC detection rates.
EpCAM can be used as a target to isolate CTCs in CRC, LC, GC, BCa, EC, HNSCC, CC and PCa, especially in CRC, while CSV can be used in most solid tumors for isolating CTCs.
上皮-间质转化（EMT）的状态因肿瘤而异。上皮细胞粘附分子（EpCAM）和细胞表面波形蛋白（CSV）分别是分离上皮性和间质性循环肿瘤细胞（CTC）最常用的靶点。本研究旨在通过比较不同实体瘤中EpCAM和CSV抗体的CTC检测率，确定一种适合每种实体瘤中富集CTC的捕获抗体。
本研究纳入了2017年4月至2018年5月期间确诊癌症且未接受过治疗的患者以及进行过CTC检测的健康人。使用EpCAM或CSV抗体，通过CytoSorter CTC系统进行CTC检测。总共收集了690例癌症患者和72例健康人的853份CTC检测结果进行分析。通过CTC检测率来确定CTC捕获抗体的性能。
EpCAM在结直肠癌（CRC）中的CTC检测率最高，为84.09%，其次是膀胱癌（BCa，78.32%）。在肝癌（HCC，25%）、胰腺癌（PDAC，32.5%）和卵巢癌（OC，33.33%）中，EpCAM抗体的CTC检测率低于40%。CSV在肉瘤中的CTC检测率最高，为90%，其次是乳腺癌（BC，85.71%）、尿路上皮癌（UC，84.62%）、卵巢癌（OC，83.33%）和膀胱癌（BCa, 81.82%））。在所有14种实体瘤中CSV抗体的CTC检测率均超过60%。除CRC外，在大多数实体瘤的CTC检测率方面，CSV的性能优于EpCAM。
EpCAM可作为分离CRC、肺癌（LC）、胃癌（GC）、BCa、子宫内膜癌（EC）、头颈部鳞状细胞癌（HNSCC）、宫颈癌（CC）和前列腺癌（PCa）中CTC的靶点，尤其是在CRC中，而CSV可用于大多数实体瘤中分离CTC。
